Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana
Sponsor: Fogarty International Center of the National Institute of Health
Listed as NCT01086878, this PHASE4 trial focuses on Acquired Immunodeficiency Syndrome and Anemia and remains completed. Sponsored by Fogarty International Center of the National Institute of Health, it has been updated 7 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fogarty International Center of the National Institute of Health
- Harvard Initiative for Global Health
- Harvard School of Public Health (HSPH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- The American Society of Tropical Medicine and Hygiene
For direct contact, visit the study record on ClinicalTrials.gov .